Active Stocks
Tue Mar 19 2024 15:58:41
  1. Tata Consultancy Services share price
  2. 3,977.55 -4.03%
  1. Tata Steel share price
  2. 148.65 -0.64%
  1. Bharti Airtel share price
  2. 1,227.85 0.23%
  1. Power Grid Corporation Of India share price
  2. 258.95 -2.28%
  1. ITC share price
  2. 409.50 -1.89%
Business News/ News / India/  Covovax proposed for kids in 12-17 group
BackBack

Covovax proposed for kids in 12-17 group

So far, more than 18.5 million vaccine doses have been administered for age group 12-14 years.
  • In March, the apex drug controller of India gave its nod to Covovax for emergency use among children above 12 years of age.
  • SII is developing Covovax through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation. (Anshuman Poyrekar/HT PHOTO)Premium
    SII is developing Covovax through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation. (Anshuman Poyrekar/HT PHOTO)

    NEW DELHI : The covid-19 working group of the National Technical Advisory Group On Immunization (NTAGI) has recommended inclusion of Serum Institute of India’s Covovax vaccine in the national covid-19 vaccination programme for 12-17 years age group, an official who is aware of the development confirmed on Sunday.

    Last month, the apex drug controller of India had approved Covovax for restricted emergency use among children above 12 years of age under certain conditions. Subsequently, the Serum Institute of India started to pursue regulatory permissions and its protocol.

    "The matter was discussed during a meeting of Covid-19 working group of NTAGI last Friday and data pertaining to the Covovax was reviewed. After detailed deliberations, the experts recommended Covovax for the inclusion in national vaccination programe to vaccinate children above 12 years of age," said the person cited above.

    Serum Institute of India refused to comment on this development, while an email sent to Health Ministry’s spokesperson was not answered till the time of publication.

    SII is developing Covovax through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation.

    It is to be noted that last month the Union Health Ministry permitted the vaccination of children above 12 years of age. Children are being vaccinated with the Biological E's Corbevax. Since then, over 18.5 million vaccine doses have been administered for age group 12-14 years.

    Under the vaccination drive, more than 1846.6 million individuals have been vaccinated so far across the country out of which 2,34,18,617 have received their precaution or booster dose.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    ABOUT THE AUTHOR
    Priyanka Sharma
    Priyanka Shamra is a health and pharma journalist with nearly nine years of field reporting experience. She is a special correspondent with Mint. Her beat includes covering the Ministry of Health and Department of Pharmaceuticals. She also covers the Ministry of Women and Child Development and the Department of Biotechnology.
    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 03 Apr 2022, 06:42 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App